Biosimulation Market Research and Global Forecast Report 2026-2036: Expansion Driven by Precision Medicine, AI-Powered In-Silico Drug Development and Rising Demand for Cost-Efficient Clinical Trials
Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The "Biosimulation Market by Product & Service, Application, and End User - Global Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.
Global biosimulation market is expected to reach approximately USD 28.50 billion by 2036 from USD 6.15 billion in 2026, at a CAGR of 16.5% during the forecast period (2026-2036).
The report provides an in-depth analysis of the global biosimulation market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, The report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.
The major factors driving the growth of the biosimulation market include the intensifying global focus on precision medicine, rapid expansion of in-silico drug development, stringent regulatory requirements, and the need to reduce trial costs. Additionally, the rapid expansion of artificial intelligence and machine learning, increasing need for high-performance pharmacokinetic and pharmacodynamic modeling, advanced computational efficiency, and digital transformation initiatives are expected to create significant growth opportunities for players operating in the biosimulation market.
In 2026, North America dominates the global biosimulation market with the largest market share, primarily attributed to massive investments in biotech R&D and the presence of leading technology innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by aggressive digital transformation initiatives and rapid adoption of advanced clinical services in China, India, and Japan. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing pharmaceutical R&D investments and increasing demand for advanced biosimulation technologies.
The key players operating in the global biosimulation market are Certara USA Inc., Simulations Plus Inc., Schrodinger Inc., Schrodinger, Genedata AG, Rhenovia Pharma, Entellus Consulting, Exscientia Ltd., Cyclica Inc., Atomwise Inc., and various other regional and emerging manufacturers, among others.
Based on Product & Service
By product & service, the software segment holds the largest market share in 2026, primarily attributed to its support for molecular modeling, complex diagnostics, and trial design in diverse research environments. These platforms offer comprehensive capabilities for predictive modeling and simulation. However, the services segment is expected to grow at a rapid CAGR during the forecast period, driven by the growing need for contract research, implementation support, and specialized consulting services. The ability to provide integrated solutions with expert support makes services highly attractive for modern pharmaceutical infrastructure.
Based on Application
By application, the drug development segment holds the largest share of the overall market in 2026, primarily due to its proven efficacy in handling high-volume clinical trial projects and providing scalable, performance-optimized solutions. The personalized medicine segment is expected to witness the fastest growth during the forecast period, driven by the shift toward precision medicine approaches, genomic analysis integration, and the complexity of advanced personalized treatment requirements. Both segments represent distinct operational requirements and technological specifications.
Based on End User
By end user, the pharmaceutical & biotechnology companies segment holds the largest share of the overall market in 2026, due to their superior data management capacity, high-performance systems, and extensive R&D investments. The CROs segment is expected to grow at a significant CAGR during the forecast period, driven by increased demand for outsourced research services, commercial logistics support, and specialized formulation expertise. Academic & research institutes represent an emerging segment with growing adoption of biosimulation tools for research and training purposes.
Key Questions Answered in The report:
Scope of the Report:
Competitive Landscape
Company Profiles
Biosimulation Market Assessment - by Product & Service
Biosimulation Market Assessment - by Application
Biosimulation Market Assessment - by End User
Biosimulation Market Assessment - by Geography
For more information about this report visit https://www.researchandmarkets.com/r/gpwz78
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.